A unique role of the DNA fragmentation factor in maintaining genomic stability

DNA fragmentation is a hallmark of apoptosis (programmed cell death). However, the biological function of apoptotic DNA fragmentation remains unclear. Here, we show that DNA fragmentation factor plays an important role for maintaining genomic stability. Inhibition or loss of the DNA fragmentation factor (DFF)/caspase-activated DNase (CAD), whose nuclease activity is responsible for digesting genomic DNA during apoptosis, led to significant increases in spontaneous or induced gene mutations, gene amplifications, and chromosomal instability in primary mouse cells and transformed human cell lines. The mechanism underlying genetic instability in DFF/CAD-deficient cells, at least in part, involves a small but significant elevation in the survival of cells exposed to ionizing radiation, suggesting that apoptotic DNA fragmentation factor contributes to genomic stability by ensuring the removal of cells that have suffered DNA damage. In support of this hypothesis are the observations of increased cellular transformation of mouse embryonic cells from the DFF/CAD-null mice and significantly enhanced susceptibility to radiation-induced carcinogenesis in these mice. These data, in combination with published reports on the existence of tumor-specific gene mutations/deletions in the DFF/CAD genes in human cancer samples, suggest that apoptotic DNA fragmentation factor is required for the maintenance of genetic stability and may play a role in tumor suppression.

[1]  S. Nilsson,et al.  Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors. , 2004, International journal of oncology.

[2]  H. Yoshida,et al.  Impaired thymic development in mouse embryos deficient in apoptotic DNA degradation , 2003, Nature Immunology.

[3]  C. Chu,et al.  Aberrant caspase-activated DNase (CAD) transcripts in human hepatoma cells , 2003, British Journal of Cancer.

[4]  Y. Fujii,et al.  Decreased expression of DFF45/ICAD is correlated with a poor prognosis in patients with esophageal carcinoma , 2002, Cancer.

[5]  Martin A. Nowak,et al.  The role of chromosomal instability in tumor initiation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Jeggo,et al.  Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner , 2002, Molecular and Cellular Biology.

[7]  C. Krona,et al.  Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours , 2002, British Journal of Cancer.

[8]  A. Berns,et al.  Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.

[9]  Daniel J. Hoeppner,et al.  Engulfment genes cooperate with ced-3 to promote cell death in Caenorhabditis elegans , 2001, Nature.

[10]  H. Horvitz,et al.  Phagocytosis promotes programmed cell death in C. elegans , 2001, Nature.

[11]  R. Versteeg,et al.  Chromosome bands 1p35–36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted , 2001, Genes, chromosomes & cancer.

[12]  Yoshiyuki Sakaki,et al.  Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line , 2000, Oncogene.

[13]  Thomas Ried,et al.  DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation , 2000, Nature.

[14]  N. Petrelli,et al.  The onset and extent of genomic instability in sporadic colorectal tumor progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  William F. Morgan,et al.  Genomic instability in Gadd45a-deficient mice , 1999, Nature Genetics.

[16]  A T Look,et al.  Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma. , 1998, Journal of pediatric surgery.

[17]  L. Kaer,et al.  Resistance to DNA fragmentation and chromatin condensation in mice lacking the DNA fragmentation factor 45. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Tonini,et al.  Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome. , 1998, Cancer letters.

[19]  P. Li,et al.  The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Nagata,et al.  Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis , 1998, Nature.

[21]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[22]  Y. Matsuura,et al.  Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Xiaodong Wang,et al.  DFF, a Heterodimeric Protein That Functions Downstream of Caspase-3 to Trigger DNA Fragmentation during Apoptosis , 1997, Cell.

[24]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[25]  J. Little,et al.  Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status , 1995, The Journal of Biological Chemistry.

[26]  G. Stark,et al.  Regulation and mechanisms of gene amplification. , 1995, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[27]  D. Housman,et al.  Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[29]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[30]  L. Loeb,et al.  Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.

[31]  W. Morgan,et al.  X-ray induction of methotrexate resistance due todhfr gene amplification , 1990, Somatic cell and molecular genetics.

[32]  B H Margolin,et al.  Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Schimke,et al.  Enhancement of the frequency of methotrexate resistance by gamma-radiation in Chinese hamster ovary and mouse 3T6 cells. , 1989, Cancer research.

[34]  N C Dracopoli,et al.  Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Liber,et al.  Mutation assay at the thymidine kinase locus in diploid human lymphoblasts. , 1982, Mutation research.

[36]  G. Wahl,et al.  The cloning and reintroduction into animal cells of a functional CAD gene, a dominant amplifiable genetic marker , 1981, Cell.

[37]  A. Wyllie.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.

[38]  R T Schimke,et al.  Gene amplification and drug resistance in cultured murine cells. , 1978, Science.

[39]  J. Little,et al.  Association of mammalian cell death with a specific endonucleolytic degradation of DNA , 1974, Nature.

[40]  Y. Matsuura,et al.  Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1. , 2001, Medical and pediatric oncology.

[41]  T. Matise,et al.  Detailed molecular analysis of 1p36 in neuroblastoma. , 2001, Medical and pediatric oncology.

[42]  C. Der,et al.  Biological assays for cellular transformation. , 1994, Methods in enzymology.